X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The authorization from Health Canada enables the Canadian Center for Vaccinology (CCfV) in Halifax to begin recruiting volunteers for the first Phase 1 clinical trial of COVAC-2 vaccine.
Lead Product(s): COVAC-2
Therapeutic Area: Infections and Infectious Diseases Product Name: COVAC-2
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Vaccine Formulation Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
Under this Partnership, Dalton will be responsible for the formulation and fill/finish of VIDO-InterVac’s COVID-19 vaccine to be used in early Phase clinical trials from Dalton`s cGMP biopharmaceutical facility in Toronto, Canada.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Recipient: Dalton Pharma Services
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 28, 2020
Details:
ZYUS will leverage its bio-pharmaceutical plant technology platform and expertise to develop and express a protein that VIDO-InterVac has identified as a potential antigen for a COVID-19 vaccine.
Lead Product(s): Plant based vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: ZYUS Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
